증권사 리포트&코멘트
https://www.prnewswire.com/news-releases/kaigene-enters-into-exclusive-licensing-agreemen…
prnewswire.com
Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases
/PRNewswire/ -- Kaigene Inc., a U.S.-based biotechnology company pioneering next-generation antibody therapeutics for autoimmune disorders, announced today...
외부 자료를 정리한 참고자료이며 투자 권유가 아닙니다. 기사·리포트의 저작권은 원저작자에게 있습니다. · 게시중단 요청